BridgeBio Pharma (BBIO) Liabilities and Shareholders Equity (2018 - 2026)
BridgeBio Pharma recorded quarterly Liabilities and Shareholders Equity of $1.4 billion in Q1 2026, up 46.47% quarter-over-quarter from $936.0 million in Q4 2025, and up 55.5% year-over-year from $881.6 million in Q1 2025.
BridgeBio Pharma's Liabilities and Shareholders Equity history runs 9 years deep, the most recent figure standing at $1.4 billion for Q1 2026.
- In Q1 2026, Liabilities and Shareholders Equity rose 55.5% year-over-year to $1.4 billion; the TTM figure through Mar 2026 stood at $4.4 billion (up 34.51% YoY), while the FY2025 annual figure was $936.0 million, up 1.82% from the prior year.
- Liabilities and Shareholders Equity came in at $1.4 billion for Q1 2026 at BridgeBio Pharma, up from $936.0 million in the prior quarter.
- In the past five years, Liabilities and Shareholders Equity ranged from a high of $1.4 billion in Q1 2026 to a low of $503.7 million in Q2 2023.
- A 5-year average of $814.9 million and a median of $813.1 million in 2022 frame the typical range for Liabilities and Shareholders Equity.
- Across the five-year window, Liabilities and Shareholders Equity tumbled 41.59% in 2023 and surged 68.26% in 2024, its largest moves.
- BridgeBio Pharma's Liabilities and Shareholders Equity stood at $623.0 million in 2022, then fell by 12.3% to $546.4 million in 2023, then soared by 68.26% to $919.3 million in 2024, then gained by 1.82% to $936.0 million in 2025, then surged by 46.47% to $1.4 billion in 2026.
- According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $1.4 billion, $936.0 million, and $998.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | 14.93 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | 37.37 Mn |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 1.73 Bn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | 78.88 Mn |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | 33.89 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 26.48 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | 23.64 Mn |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 40.87 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 5.13 Bn |
| 10 | BridgeBio Pharma | 12.91 Bn | 11.98 Bn | 184.58 Mn | 1.37 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.37 Bn |
| Dec 31, 2025 | 936.03 Mn |
| Sep 30, 2025 | 998.25 Mn |
| Jun 30, 2025 | 1.08 Bn |
| Mar 31, 2025 | 881.64 Mn |
| Dec 31, 2024 | 919.34 Mn |
| Sep 30, 2024 | 664.98 Mn |
| Jun 30, 2024 | 794.38 Mn |
| Mar 31, 2024 | 849.33 Mn |
| Dec 31, 2023 | 546.38 Mn |
| Sep 30, 2023 | 655.01 Mn |
| Jun 30, 2023 | 503.66 Mn |
| Mar 31, 2023 | 625.68 Mn |
| Dec 31, 2022 | 623.04 Mn |
| Sep 30, 2022 | 728.74 Mn |
| Jun 30, 2022 | 862.23 Mn |
| Mar 31, 2022 | 813.15 Mn |
| Dec 31, 2021 | 1.01 Bn |
| Sep 30, 2021 | 781.52 Mn |
| Jun 30, 2021 | 1.08 Bn |
| Mar 31, 2021 | 1.09 Bn |
| Dec 31, 2020 | 703.59 Mn |
| Sep 30, 2020 | 787.69 Mn |
| Jun 30, 2020 | 905.23 Mn |
| Mar 31, 2020 | 989.80 Mn |
| Dec 31, 2019 | 631.68 Mn |
| Sep 30, 2019 | 640.53 Mn |
| Jun 30, 2019 | 3.31 Mn |
| Dec 31, 2018 | 464.94 Mn |